IRIS
PUPPO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 19.606
AS - Asia 2.005
NA - Nord America 1.460
Continente sconosciuto - Info sul continente non disponibili 269
SA - Sud America 191
AF - Africa 32
OC - Oceania 2
Totale 23.565
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 19.270
US - Stati Uniti d'America 1.353
SG - Singapore 797
CN - Cina 572
VN - Vietnam 294
FR - Francia 152
BD - Bangladesh 130
BR - Brasile 108
HK - Hong Kong 69
DE - Germania 38
FI - Finlandia 34
AR - Argentina 33
CA - Canada 33
MX - Messico 25
JP - Giappone 22
IQ - Iraq 18
GB - Regno Unito 15
ID - Indonesia 14
IN - India 14
ES - Italia 13
CH - Svizzera 12
IE - Irlanda 11
JM - Giamaica 11
MA - Marocco 11
NL - Olanda 11
RU - Federazione Russa 11
TH - Thailandia 11
VE - Venezuela 11
CO - Colombia 10
CR - Costa Rica 9
PY - Paraguay 9
ZA - Sudafrica 9
HN - Honduras 8
PL - Polonia 8
TR - Turchia 8
UA - Ucraina 7
EC - Ecuador 6
MY - Malesia 6
PH - Filippine 6
PK - Pakistan 6
JO - Giordania 5
PE - Perù 5
PR - Porto Rico 5
SA - Arabia Saudita 5
KR - Corea 4
MD - Moldavia 4
OM - Oman 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
CL - Cile 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
GR - Grecia 3
IR - Iran 3
TW - Taiwan 3
UY - Uruguay 3
AL - Albania 2
AU - Australia 2
AZ - Azerbaigian 2
EG - Egitto 2
GT - Guatemala 2
LT - Lituania 2
MT - Malta 2
NP - Nepal 2
RO - Romania 2
SC - Seychelles 2
TN - Tunisia 2
UZ - Uzbekistan 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BY - Bielorussia 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
CZ - Repubblica Ceca 1
GE - Georgia 1
GP - Guadalupe 1
HR - Croazia 1
LC - Santa Lucia 1
LV - Lettonia 1
LY - Libia 1
ML - Mali 1
NG - Nigeria 1
PT - Portogallo 1
RS - Serbia 1
SE - Svezia 1
TC - Turks e Caicos 1
TJ - Tagikistan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 23.298
Salva come PNG Salva come JPEG
Città #
Genova 12.123
Genoa 4.216
Rapallo 1.549
Vado Ligure 1.215
Singapore 370
San Jose 324
Lauterbourg 143
Ashburn 134
Beijing 108
Ho Chi Minh City 93
Hong Kong 62
Hanoi 59
New York 59
Santa Clara 47
Bordighera 42
Helsinki 33
Frankfurt am Main 30
Los Angeles 30
Council Bluffs 28
Chicago 22
Buffalo 18
Milan 17
Tokyo 17
Mexico City 16
Tianjin 16
Dallas 13
Haiphong 13
Phoenix 13
Rome 13
Charlotte 12
Da Nang 12
Zurich 12
Boston 11
Orem 11
St Louis 11
Amsterdam 10
Dublin 10
São Paulo 10
Boardman 9
Naples 9
Madrid 8
Detroit 7
Jacksonville 7
Queens 7
Shanghai 7
Baghdad 6
Kingston 6
Lima 6
Miami 6
Montreal 6
Rio de Janeiro 6
San José 6
Warsaw 6
Washington 6
Amman 5
Bangkok 5
Biên Hòa 5
Bogotá 5
Brooklyn 5
Bắc Ninh 5
Can Tho 5
Florence 5
Minneapolis 5
Newark 5
Riverside 5
Seattle 5
Acalanes Ridge 4
Chennai 4
City of London 4
Dhaka 4
Philadelphia 4
Roseville 4
Thái Nguyên 4
Toronto 4
Asunción 3
Atlanta 3
Augusta 3
Bắc Giang 3
Canton 3
Cape Town 3
Carnegie 3
Charleston 3
Columbus 3
Curitiba 3
Dayton 3
Des Moines 3
El Progreso 3
Fayetteville 3
Grand Forks 3
Guangzhou 3
Hialeah 3
Houston 3
Kuala Lumpur 3
Kyiv 3
La Paz 3
Lancaster 3
Las Vegas 3
London 3
Louisville 3
Milwaukee 3
Totale 21.200
Salva come PNG Salva come JPEG
Nome #
Infection risk associated with anti-TNF-α agents: A review 244
A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer 233
Autoimmune intrahepatic cholangiopathy associated with antiphospholipid antibody syndrome 232
Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis 231
Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response. 214
Effect of clotting factors concentrates on lymphocyte and neutrophil function in vitro 208
Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference 207
Vaccine-preventable infections in Systemic Lupus Erythematosus 206
ACUTE CARDIAC FAILURE AND IGA NEPHROPATHY: AN UNCOMMON SLE ONSET 205
Immunogenicity of infliximab and adalimumab: What is its role in hypersensitivity and modulation of therapeutic efficacy and safety? 203
Allergen-driven HLA-G expression and secretion in peripheral blood mononuclear cells from allergic rhinitis patients 200
Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: an early predictor marker of response? 196
Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications 196
TNF-α gene polymorphisms: association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis 196
Improvement in esophageal motor abnormalities in systemic sclerosis patients treated with cyclosporine: comment on the article by Clements et al. 194
Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy 194
The antiphospholipid syndrome: from pathophysiology to treatment 190
S-adenosil-L-methionine is able to reverse the immunosuppressive effects of chenodeoxycholic acid in vitro. 190
Blunted coronary flow reserve in systemic sclerosis: a sign of cardiac involvement in asymptomatic patients 184
Current recommendation to reduce the burden of bacterial and viral infections in patients affected by systemic lupus erythematosus 183
Possible differences in the mechanism(s) of action of different glucocorticoid hormone compounds. 182
Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis 178
Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis 178
Immunoregulatory Role of HLA-G in Allergic Diseases 177
Remission of Brucella endocarditis in a patient with mitral valve mechanical prosthesis by antibiotic therapy alone: a case report 177
Soluble HLA-G and HLA-A,-B,-C serum levels in patients with allergic rhinitis 176
Behavior of serum human major histocompatibility complex class I antigen levels in human immunodeficiency virus-infected patients during antiretroviral therapy: correlation with clinical outcome 176
General surgery, translational lymphology and lymphatic surgery 175
Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study 174
Soluble HLA-G molecule in patients with perennial allergic rhinitis. 172
Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy 169
Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events 168
Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). 168
Anti-tumour necrosis factor-a treatment with infliximab for disseminated granuloma annulare 167
An Uncommon Presentation of Pancreatic Carcinoma 166
Defective expression and function of the leukocyte associated ig-like receptor 1 in B lymphocytes from systemic lupus erythematosus patients 165
Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. 163
In vitro immunosuppressive activity of soluble HLA class I and Fas ligand molecules: do they play a role in autologous blood transfusion? 162
Soluble serum HLA-G and HLA-A, -B, -C molecules in patients with seasonal allergic rhinitis exposed to pollens. 161
Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction. 160
Apoptosis in the Homeostasis of the Immune System and in Human Immune Mediated Diseases 159
Genetic factors and systemic sclerosis 159
Effects of antagomiRs on different lung diseases in human, cellular, and animal models 159
Immune cell circulating subsets are affected by gonadal function. 158
Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes 156
Soluble HLA class I molecules induce natural killer cell apoptosis through the engagement of CD8: evidence for a negative regulation exerted by members of the inhibitory receptor superfamily 156
Effect of levamisole on postoperative immunosuppression 156
Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: A prospective, observational cohort 156
HLA-G expression in gastric carcinoma: clinicopathological correlations and prognostic impact 156
Soluble HLA class I and Fas ligand molecules in blood components and their role in the immunomodulatory effects of blood transfusions. 155
Behavior of non-classical soluble HLA class G antigens in human immunodeficiency virus 1-infected patients before and after HAART: comparison with classical soluble HLA-A, -B, -C antigens and potential role in immune-reconstitution. 155
Update upon the infection risk in patients receiving TNF alpha inhibitors 155
Efficacy of cilostazol for the treatment of Raynaud’s phenomenon in systemic sclerosis patients 153
A case of transposition of the great arteries in a female infant of a HIV-1 infected woman. Potential teratogenic effect of antiretroviral drugs. 153
Serum zinc levels in patients with multiple myeloma ad waldenstrom's disease 152
Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis 152
Endothelial dysfunction in rheumatic autoimmune diseases. 152
Plicometer skin test: a new technique for the evaluation of cutaneous involvement in systemic sclerosis. 149
FRI0199 EFFECTIVENESS AND SAFETY OF BELIMUMAB IN PATIENTSWITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A LARGE, NATIONWIDE, MULTICENTRIC STUDY 149
Increased beta2-microglobulin-free HLA class I heavy chain serum levels in the course of immune responses to viral antigens and to mismatched HLA antigens. 148
Potential use of TNF-α inhibitors in systemic sclerosis. 146
Soluble HLA class I/CD8 ligation triggers apoptosis in EBV-specific CD8+ cytotoxic T lymphocytes by Fas/Fas-ligand interaction 145
Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. 145
Immunohistochemical evidnce of HLA-G expression in extravillous trophoblast invading decidual tissues. 144
Fas, Fas ligand, and transfusion immunomodulation 144
Current views on diagnostic approach and treatment of lymphedema 144
Low expression of inhibitory natural killer receptors in CD8 cytotoxic T lymphocytes in long-term non-progressor HIV-1-infected patients 144
Intima-media thickness: a marker of accelerated atherosclerosis in women with systemic lupus erythematosus 144
Increased serum concentration of soluble HLA-DR antigens in HIV infection and following transplantation. 143
dsDNA-, nucleohistone- and DNASE I-reactive T lymphocytes in patients affected by systemic lupus erythematosus: correlation with clinical disease activity. 142
Immune regulatory properties of corticosteroids: prednisone induces apoptosis of human T lymphocytes following the CD3 down-regulation. 142
Free radicals and endothelial dysfunction: potential positive effects of TNF-α inhibitors. 142
Immunogenicity of infliximab and adalimumab 142
Lymphatic microsurgery to treat lymphedema: techniques and indications for better results. 141
Effects of TNF-α inhibitors upon the mechanisms of action of VEGF. 141
Accelerated atherosclerosis in patients with Systemic Lupus Erythematosus. 140
Increased level of serum HLA class I antigens in HIV infection. Correlation with disease progression. 138
Soluble HLA class I and class II molecule levels in serum and cerebrospinal fluid of multiple sclerosis patients. 138
Immune homeostasis requires several biologic factors including glucocorticoid hormones 138
Emerging role of vitamin D in autoimmune diseases: An update on evidence and therapeutic implications 138
Il-33/il-31 axis in immune-mediated and allergic diseases 138
Sublingual immunotherapy reduces soluble HLA-G and HLA-A,-B,-C serum levels in patients with allergic rhinitis. 137
Determination of lymphotoxin-α levels in patients with psoriatic arthritis undergoing etanercept treatment 137
DsDNA-specific T-cell lines in systemic lupus erythematosus patients: data suggesting their oligoclonality. 136
Antiphospholipid syndrome and reversible posterior leukoencephalopathy syndrome. 136
Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: current evidences upon safety and immunogenicity 136
Immunoglobulin production pattern is allergen-specific in polysensitized patients. 135
Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis 135
Serum HLA class I antigens: markers and modulators of an immune response? 134
Double-stranded deoxyribonucleic acid binds to HLA class II molecules and inhibits HLA class II-mediated antigen presentation. 133
CD4+ CD25+ T regulatory cells functionin venom imenoptera atopic patients before and during allergen immunotherapy. 132
New glucocorticoids. Mechanisms of immunological activity at the cellular level and in the clinical setting. 132
Decreased lymphocyte blastogenesis, IL2 production and NK activity following nifedipine administration to healthy humans. 131
The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases 131
Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. 131
Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: Current views upon safety and immunogenicity. 131
Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept? 130
Immunotherapy with intralesional and systemic interleukin-2 of patients with non-small-cell lung cancer. 130
Soluble HLA-G serum levels in patients with the Acquired Immunodeficiency Syndrome affected by different AIDS-defining conditions before and after anti-retroviral treatment 129
Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. 128
Totale 16.111
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.517
article - articoli 73.258
book - libri 522
conference - conferenze 717
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.020
Totale 151.034
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.013 60 166 134 238 60 128 121 479 90 181 100 256
2022/20231.840 167 109 31 188 319 331 2 143 313 13 198 26
2023/2024909 33 162 13 107 64 146 79 71 52 8 56 118
2024/20252.976 103 210 94 185 458 287 293 436 111 115 292 392
2025/20264.974 631 133 263 449 689 479 835 212 310 475 251 247
2026/2027508 508 0 0 0 0 0 0 0 0 0 0 0
Totale 23.565